Jason Wittes analyst

Currently out of the existing stock ratings of Jason Wittes, 100 are a BUY (86.21%), 16 are a HOLD (13.79%).

Jason Wittes

Work Performance Price Targets & Ratings Chart

Analyst Jason Wittes, has had 58.48% of price targets met with an average potential upside of 44.27%, reached in 281 days on average. Previously, Jason Wittes worked at ROTH MKM, AEGIS, LOOP CAPITAL, NORTHLAND CAPITAL MARKETS, BREAN.

Jason Wittes has documented 227 price targets and ratings displayed on 30 stocks. The coverage was on Healthcare, Consumer Cyclical sectors.

Most recent stock forecast was given on IRMD, at 10-Feb-2026.

Wall Street Analyst Jason Wittes

Analyst best performing recommendations are on PGNX (PROGENICS PHARMACEUTICALS).
The best stock recommendation documented was for NUVA (NUVASIVE) on 6/7/2016. The price target of $60 was fulfilled within 2 days with a profit of $2.11 (3.64%), with a performance score of 18.22.

Average potential price target upside

ARAY ATEC GMED STXS Stereotaxis SYK Stryker TFX Teleflex ZBH VAR Varian Medical Systems BWAY Brainsway Ltd NUVA NuVasive NVCR MASI CLDX LMAT MDWD PGNX Progenics Pharmaceuticals ENOV OFIX IRMD TLSI TriSalus Life Sciences INO TGTX TG Therapeutics VRAY ViewRay MGRM MDXG DERM WMGI Wright Medical Group N.V DRI Darden Restaurants FBIO SPRY ARS Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 08-Jul-2026

4 months 9 days ago
(08-Jul-2026)

1/2 (50%)

$1.4 (233.33%)

277

Buy Since 02-May-2024

$5

1 years 3 months 3 days ago
(14-Aug-2025)

0/2 (0%)

$3.54 (242.47%)

Buy Since 23-May-2016

$7

$9

2 years 6 months 15 days ago
(02-May-2024)

0/8 (0%)

$5.46 (354.55%)

Buy Since 23-Jun-2022

$6.5

3 years 8 days ago
(09-Nov-2023)

0/2 (0%)

$4.06 (166.39%)

Buy Since 08-Nov-2023

$8

$9

3 years 9 days ago
(08-Nov-2023)

0/2 (0%)

$5.34 (200.75%)

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?